Company intelligence / Profile preview

Shanghai Furen Medicine R&D Co., Ltd.

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Licensed AZD0364, an ERK1/2 inhibitor small molecule, from AstraZeneca in 2019 for development in NSCLC and solid tumors in China; preclinical efficacy demonstrated; IND accepted by US FDA in 2018.

Therapeutic areas: Oncology
Modalities: Small moleculeCell therapyLarge molecule
Industry: Biotech

Partnerships

AstraZeneca (exclusive license for AZD0364 in China)

Beyond the preview

Go deeper on Shanghai Furen Medicine R&D Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Furen Medicine R&D Co., Ltd..

Explore the full profile